Drug developer Bicara Therapeutics Inc., advised by Goodwin, announced on Friday plans to raise around $200 million in its initial public offering, with the proceeds going toward developing bifunctional antibodies designed to treat solid tumors. The majority of the proceeds will be used to advance the development of ficerafusp alfa in head and neck squamous cell carcinoma treatment, with smaller portions of the proceeds going toward funding the expansion of the drug's development in additional patient populations and other solid tumors, the filing said. The company said that the main purpose of its IPO is to facilitate future access to the public equity markets, increase its visibility in the marketplace and obtain additional capital. The Goodwin team advising Bicara includes Kingsley Taft, partner and co-chair of Goodwin's Life Sciences group, Gabriela Morales-Rivera, partner in Goodwin’s Life Sciences group, and Amarilice Young, associate in the Business Law Department. For more information on Biacara Therapeutics public offering, read the article on Law360.